Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review.

For that subgroup, patients receiving fremanezumab experienced numerically greater reductions in depressive symptoms (based on mean PHQ-9 scores) than those receiving placebo, although these differences did not reach statistical significance (quarterly fremanezumab, –10.9 [77% reduction]; monthly fremanezumab, –9.8 [66%]; placebo,–9.2 [61%]; P = .113 and P = .558, respectively).

also in 111,027 other papers